--澳大利亚研究人员进行了一项长达七年的研究显示，相较于胰岛素注射，胰岛素泵能够更有效地控制患有一型糖尿病儿童体内的血糖水平。这是迄今为止对胰岛素泵在儿童糖尿病领域最大规模和最长时间跟踪研究。来自澳大利亚Princess Margaret Hospital for Children的研究人员在诺和诺德公司的资助下，对年龄在2到19岁之间使用胰岛素泵的儿童研究后发现，这些患者平均有0.6%的血糖降低，这种差异在整个7年的研究周期中始终存在。研究同时显示，胰岛素泵也降低了严重的低血糖症出现的可能性。研究人员总结到，相对于胰岛素注射疗法，胰岛素泵疗法在儿童治疗中能够更有效的控制儿童患者体内血糖的变化。

详细英文报道：

A new Australian 7-year study showed that insulin pumps improved glycemic control and reduced hypoglycemia compared with insulin injections among children with Type 1 diabetes. It was the largest study of insulin pump use in children and had the longest follow-up period of any study to date.

Researchers at the Princess Margaret Hospital for Children in Perth, with funding from Novo Nordisk ($NVO), found that children between the ages of 2 and 19 who used an insulin pump had on average 0.6% reduced blood sugar, a difference that remained for all 7 years, according to the study in the journal Diabetologia.

The study also showed that insulin pumps reduced the number of episodes of severe hypoglycemia, cutting it in half in the first year of pump therapy from 14.7 events per patient per year to 7.2. For those children on injection therapy, however, severe events increased in number from 6.8 to 10.2.

The study notes that "it does reflect 'real life' experience in a large population-based sample over a prolonged period" and concluded that "insulin pump therapy is associated with a significant improvement in glycemic control, which is sustained over many years."

"Most studies report an improvement in HbA1c associated with pump therapy, although some report no improvement or an initial improvement followed by a return to pre-pump levels after a short time," the researchers wrote in the study.

And in an email to MedPage Today, lead author Elizabeth Davis wrote: "We know that long-term glycemic control correlates with chronic microvascular complications, so we would predict that over a longer period of time this improvement in HbA1c will be associated with reduced microvascular complications."